Lilly confirms date and conference call for fourth-quarter 2024 financial results and 2025 financial guidance announcement PR Newswire INDIANAPOLIS, Jan. 23, 2025 INDIANAPOLIS, Jan. 23, 2025...
FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease PR Newswire INDIANAPOLIS, Jan. 15, 2025 In the pivotal...
Lilly provides update on 2024 revenue guidance, announces 2025 revenue guidance PR Newswire INDIANAPOLIS, Jan. 14, 2025 2024 revenue is expected to be approximately $45.0 billion for the full...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
기호 | 가격 | 볼륨 |
---|
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관